Trial Profile
A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2016
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Coronary artery disease
- Focus Diagnostic use; Registrational
- Acronyms EXERRT
- Sponsors Astellas Pharma
- 16 Nov 2016 Results of quantitative myocardial perfusion presented at the 89th Annual Scientific Sessions of the American Heart Association
- 22 Apr 2015 New trial record